Larimar Therapeutics (LRMR) Stock Forecast & Price Target

$5.90 -0.18 (-2.96%)

(As of 10:02 AM ET)

Larimar Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 11 Analyst Ratings

Sell
0

Hold
0

Buy
11

Based on 11 Wall Street analysts who have issued ratings for Larimar Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 10 have given a buy rating, and 1 has given a strong buy rating for LRMR.

Consensus Price Target

$20.43
246.25% Upside

According to the 11 analysts' twelve-month price targets for Larimar Therapeutics, the average price target is $20.43. The highest price target for LRMR is $26.00, while the lowest price target for LRMR is $14.00. The average price target represents a forecasted upside of 246.25% from the current price of $5.90.

Get the Latest News and Ratings for LRMR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Larimar Therapeutics and its competitors.

LRMR Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$20.43	$20.43	$21.33	$11.83
Forecasted Upside	246.25% Upside	171.30% Upside	171.42% Upside	256.43% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

LRMR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LRMR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Larimar Therapeutics Stock vs. The Competition

Type	Larimar Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.09	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	233.26% Upside	26,931.27% Upside	9.84% Upside
News Sentiment Rating	Positive News See Recent LRMR News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	William Blair 2 of 5 stars		Reiterated Rating	Outperform
11/18/2024	HC Wainwright 2 of 5 stars	E. White Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00	+134.74%
10/16/2024	Oppenheimer 3 of 5 stars		Initiated Coverage	Outperform	$26.00	+250.40%
10/3/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00	+249.76%
9/4/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Skorney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$16.00	+131.21%
5/31/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$25.00 ➝ $25.00	+214.07%
5/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$10.00 ➝ $14.00	+74.13%
4/3/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Park Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/3/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$25.00	+239.67%
2/20/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Jubinville Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/17/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$12.00 ➝ $14.00	+283.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:28 AM ET.

LRMR Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Larimar Therapeutics is $20.43, with a high forecast of $26.00 and a low forecast of $14.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares.
: According to analysts, Larimar Therapeutics's stock has a predicted upside of 246.25% based on their 12-month stock forecasts.
: Over the previous 90 days, Larimar Therapeutics's stock had 1 upgrade by analysts.
: Larimar Therapeutics has been rated by research analysts at Baird R W, HC Wainwright, Oppenheimer, Robert W. Baird, Wedbush, and William Blair in the past 90 days.
: Analysts like Larimar Therapeutics more than other "medical" companies. The consensus rating for Larimar Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LRMR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NASDAQ:LRMR) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Stock Forecast & Price Target